Both companies will expand their cooperation through the distribution of medical cannabis products in the highly attractive Czech and Swiss markets DUSSELDORF, Germany, BARCELONA, Spain
/PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), and Panaxia.
Following the adaptation of the European production standard EU-GMP, Panaxia will start production in the local facility in Malta. Obtaining the license allows.
- Net Israeli revenues in 2021 increased 38% to 83.6 million. - Initial revenues from medical cannabis oils export from Israel, which began at the end of 2020,.